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Phase II Trial of Neoadjuvant Therapy with Carboplatin,
Gemcitabine plus Thalidomide for Stages IIB and III
Non-small Cell Lung Cancer
Arkadiusz Z. Dudek, MD, PhD,* Krzysztof Lesniewski-Kmak, MD,* Timothy Larson, MD,†
Konstantin Dragnev, MD,‡ Rachel Isaksson, MS,§ Vinita Gupta, PhD, Michael A. Maddaus, MD,¶
and Robert A. Kratzke, MD*
Introduction: This phase II study assessed the clinical activity of
neoadjuvant therapy with carboplatin, gemcitabine, and thalidomide
in patients with stage IIB to IIIA non-small cell lung cancer
(NSCLC). A secondary goal was to assay a panel of candidate serum
biomarkers before and after neoadjuvant therapy.
Methods: Patients received three 21-day cycles consisting of gem-
citabine (1000 mg/m2) on days 1 and 8, carboplatin (area under the
curve, 5.5) on day 1, and thalidomide (200 mg) daily after a gradual
dose escalation.
Results: A total of 22 patients (12 women, 10 men) were enrolled
with inoperable stage IIB NSCLC (32%) or III NSCLC (68%).
Median age was 53 years (range: 32–78). Sixty-six cycles of
neoadjuvant therapy were administered with 10 cycles requiring
dose reductions (21.28%). Response rates were 70% for partial
response (n  14), 20% for disease stability (n  4), and 10% for
disease progression (n  2). Disease in 14 patients (70%) was
downstaged, allowing for 10 lobectomies (45.5%), one bilobectomy
(4.5%), and 3 pneumonectomies (13.64%). Grades 3/4 hematologic
events included neutropenia (55%), thrombocytopenia (14%), and
anemia (14%). Grade 3 skin toxicity was reported in one patient due
to thalidomide. Posttreatment increases from baseline in serum
levels of angiopoietin (100 pg/ml), platelet/endothelial cell adhesion
molecule 1 (100 pg/ml), hepatocyte growth factor (100 pg/ml),
vascular endothelial growth factor (10 pg/ml), and interleukin-8 (10
pg/ml) corresponded to a reduction in the probability of death (p 
0.09, 0.055, 0.097, 0.052, and 0.095, respectively). Overall survival
was 3.6 years (95% CI: 1.938–).
Conclusion: This neoadjuvant regimen was well tolerated and effec-
tive in inoperable NSCLC and warrants additional investigation.
Key Words: Neoadjuvant chemotherapy, Carboplatin, Gemcitab-
ine, Thalidomide, Non-small cell lung cancer, Serum biomarkers.
(J Thorac Oncol. 2009;4: 969–975)
Non-small cell lung cancer (NSCLC) is the most commoncause of cancer-related mortality in Western countries.
In the United States, NSCLC incidence and mortality are
expected to be 215,020 and 161,840, respectively, in 2008.1
Early-stage NSCLC is most effectively treated with surgery
followed by adjuvant chemotherapy.2–5 Surgical treatment of
locally advanced NSCLC is often not possible due to tumor
invasion into the mediastinum or adjacent chest structures. In
such circumstances, chemoradiotherapy is the best therapeu-
tic option. However, for some patients with inoperable
NSCLC, neoadjuvant chemotherapy with the goal of down-
staging tumors before surgical resection can be a treatment
option with a better chance of success. In early clinical trials,
resection rates and survival were improved by downstaging
of disease with neoadjuvant chemotherapy.6–8 A large phase
III randomized trial of neoadjuvant chemotherapy showed
that patients with NSCLC in stages IB, II, or IIIA had an
overall 23% reduction in mortality and 10-month median
improvement in survival compared with surgery alone.9 In
addition, 11% of patients achieved a complete pathologic
response with chemotherapy.
Carboplatin and gemcitabine are commonly used in
chemotherapy schedules for the treatment of advanced
NSCLC. However, the effectiveness of chemotherapy
reaches a plateau, which has led to attempts to supplement
existing chemotherapy regimens with agents with different
mechanisms of action. Thalidomide may not only have anti-
angiogenic properties,10 but also could be immunomodula-
tory.11 Thalidomide is also thought to act through inhibition
of tumor necrosis factor alpha synthesis by accelerating
mRNA degradation.12 Thalidomide was initially used in the
mid-twentieth century to treat morning sickness in pregnant
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women and was withdrawn after causing several cases of
fetal injury. In the 1990s, thalidomide started to be investi-
gated as a potential cancer treatment and currently is widely
used in myeloma. The safety of thalidomide in combination
with carboplatin and paclitaxel or irinotecan has been dem-
onstrated in unresectable, stage IIIA to IV patients with
NSCLC.13,14 The purpose of our multiinstitutional study was
to evaluate prospectively the clinical outcomes of patients
with locally advanced NSCLC treated with combination neo-
adjuvant therapy consisting of carboplatin, gemcitabine, and
thalidomide. A secondary goal of this study was to assay a
panel of nine candidate serum proteins before and after the
administration of neoadjuvant therapy to identify possible
biomarkers to treatment response.
PATIENTS AND METHODS
Patient Selection
Patients were eligible for study enrollment if they were
at least 18 years old with a confirmed diagnosis of stage II or
IIIA NSCLC. No prior chemotherapy or radiotherapy was
allowed. Prior resection of lung disease was allowed provided
at least 5 years had elapsed between prior surgery and
registration. At least one unidimensionally measurable lesion
on chest radiograph was required as defined by RECIST
criteria. Eligibility criteria also included the following:
Karnofsky Performance Status 70, adequate hematopoietic
counts (absolute neutrophil count 1.5  109/liter, platelet
count 100  109/liter, hemoglobin 10g/dl), liver function
(total bilirubin 2 mg/dl and serum glutamic oxaloacetic
transaminase/aspartate transaminase 3  the upper limit of
normal), and renal function (creatinine 2 mg/dl). Patients
were excluded if they had prior malignancy other than ade-
quately treated basal or squamous cell skin cancer, in situ
cervical cancer, or other cancer from which the patient had
been disease free for at least 5 years. Patients with concurrent
malignancy were eligible if the stage and nature of the cancer
was unlikely to affect survival for the next 3 years. No
concurrent serious medical illnesses, grade 2 or higher pe-
ripheral neuropathy at time of study enrollment, pregnancy,
or child nursing were allowed. Patients with tumor involving
the superior sulcus (Pancoast tumor) were excluded. The
study was carried out according to the principles of the
Declaration of Helsinki and was approved by the University
of Minnesota Institutional Review Board.
Treatment Schedule
The treatment schedule consisted of three 21-day cy-
cles. Gemcitabine was administered intravenously at a dose
of 1000 mg/m2 for more than 30 minutes on days 1 and 8 of
each cycle. Carboplatin was administered intravenously as a
30-minute infusion on day 1 of each cycle after administra-
tion of gemcitabine. The administration of carboplatin and
gemcitabine was separated by a 30-minute infusion of 100 ml
of saline. The dose of carboplatin was adjusted for renal
dysfunction to achieve a calculated area under the curve
(AUC) of 5.5 as defined by the Calvert formula: AUC dose
5.5  (glomerular filtration rate  25). Thalidomide was
taken as a single daily dose of 200 mg orally if tolerated, after
a gradual dose escalation (day 1: 50 mg, day 2: 100 mg, and
day 3: 150 mg).
Dose Modification
Dose adjustments to gemcitabine and carboplatin were
made at the beginning of a new cycle depending on labora-
tory results or symptoms encountered in the previous cycle.
The dose of gemcitabine could also be adjusted on day 8
based on the toxicity observed on day 1 at the start of a cycle.
Up to two dose reductions per patient were allowed for gemcit-
abine (800-600 mg/m2), carboplatin (AUC, 5–4.5), and thalid-
omide (150-100 mg). Gemcitabine could be discontinued if
pneumonitis grade 2 or higher developed in a given cycle. Other
grade 3 and 4 nonhematological toxicities could be reason for
dose reduction on subsequent cycles or discontinuation. A new
cycle of treatment was begun when the granulocyte count was
1500/mm3, the platelet count was 100,000/mm3, and treat-
ment-related diarrhea was fully resolved.
Patient Evaluation
Baseline evaluation included the following: clinical his-
tory, physical examination, electrocardiography, complete blood
count with differential, blood chemistry (bilirubin, alkaline
phosphatase, alanine transaminase, aspartate transaminase,
blood urea nitrogen, creatinine, phosphorus, calcium, glu-
cose, total protein, albumin, and electrolytes), imaging nec-
essary for tumor measurement, and mediastinoscopy. Com-
plete blood count was performed on days 1 and 8 of treatment
cycle, and blood chemistry was performed on day 1 only. All
toxicities were graded on National Cancer Institute’s Com-
mon Toxicity Criteria (CTCAE 3.0). Responses were evalu-
ated by computed tomography after cycle 3 using RECIST
criteria. Other imaging was done if clinically appropriate.
Complete response (CR) was defined as disappearance of all
target lesions and all nontarget lesions. Partial response (PR)
was defined as at least a 30% decrease in the sum of the
largest diameter (LD) of target lesions, taking as a reference
the baseline LD sum. Progressive disease (PD) was defined as
at least a 20% increase in the sum of the LD of target lesions,
taking as a reference the smallest LD sum recorded since the
treatment started. PD was also indicated if there was the
appearance of one or more new lesions or unequivocal
progression of existing nontarget lesions. Stable disease (SD)
was defined as neither the sufficient shrinkage to qualify for
PR nor the sufficient increase to qualify for PD. Pathologic
complete remission was defined as no viable tumor cells in
the tumor specimen as determined by light microscopy.
Correlative Markers
Nine serum markers were evaluated before and after the
treatment for their correlation with clinical outcomes. These
serum proteins included angiopoietin 2 (pg/mL), follistatin
(pg/mL), hepatocyte growth factor (pg/mL), interleukin-8
(IL-8), granulocyte colony-stimulating factor (pg/mL), hu-
man platelet-derived growth factor- (pg/mL), vascular en-
dothelial growth factor (VEGF, pg/mL), leptin (pg/mL), and
platelet/endothelial cell adhesion molecule 1 (PECAM 1,
pg/mL). To detect serum levels of these potential biomarkers,
the Bio-Plex Pro human angiogenesis 9-plex complete kit
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was used. The first step of the procedure was to incubate
patient serum samples with the microspheres for 30 minutes
at ambient temperature with agitation. The microspheres
were then washed with washing buffer to remove unbound
materials. Biotinylated detection antibodies were added and
incubated to allow for the formation of sandwich complexes.
After the removal of excess detection antibodies, the sand-
wich complexes were added to a solution of streptavidin-
phycoerythrin (PE) conjugate and incubated. After removing
excess streptavidin-PE conjugate, the final mixture was
passed through the Bio-Plex array reader that measures the
fluorescence of bound streptavidin-PE conjugate.
Statistical Methods
The study was designed as a Simon’s two-stage clinical
trial to test the null hypothesis that the probability of a
response (complete or partial) was 25% versus the alterna-
tive that the probability was 55%. There was a 4.7%
probability of type I error (false positive) and 14.3% proba-
bility of type II error (false negative). The trial would termi-
nate after the first stage if only two or fewer of eight subjects
would respond to the treatment. The trial would be rejected
for lack of efficacy after the second stage if only eight or
fewer of 21 total subjects would respond to the treatment.
Serum biomarker levels for patients who completed all
three treatment cycles were further explored. Changes in each
serum biomarker were determined for each patient, compar-
ing their before and after treatment values. Mean serum
marker values were also determined for before and after
treatment changes. Overall, survival times were calculated
from the study entry date to the date of death or were
censored at the date of last contact for patients still alive.
Disease-free survival times were calculated from the study
entry date to the date of recurrence or the date of death,
whichever came first, or were censored at the date of last
contact for patients still alive and who did not recur. Univar-
iate proportional hazard models were fit for each serum
marker, and corresponding hazard ratios were reported for
both overall survival and disease-free survival. All analyses
were performed using SAS version 9.1.
RESULTS
Patient Characteristics
Twenty-two chemonaïve patients with stage II or IIIA
NSCLC were treated from October 2002 to December 2007.
The male-to-female ratio was 10/12 (45.5/54.5%). The me-
dian age was 53 years (range: 32–78 years). Patient charac-
teristics are shown in Table 1. Although not an eligibility
requirement, every patient was referred to the study by a
surgeon due to inoperable tumor.
Toxicity
In general, the safety profile of combining gemcitabine,
carboplatin, and thalidomide in this treatment schedule was
found to be similar to the safety profile of gemcitabine-
carboplatin doublet. Grade 3 neutropenia was the most com-
mon hematological side effect and was experienced by 12
patients (55%). Of these 12, only one patient (4%) developed
grade 4 neutropenia after receiving an additional cycle of
chemotherapy. Grades 3 and 4 thrombocytopenia were seen
in two patients (8%) and one patient (4%), respectively.
Three patients (12%) developed grade 3/4 anemia. Six pa-
tients receiving chemotherapy were treated for neutropenia
with granulocyte colony-stimulating factor. Five patients
were treated with erythropoietin, and four of these went on to
receive transfusions of two units of red blood cells. Thalid-
omide was stopped after day 1 of the first cycle of treatment
in one patient due to grade 3 skin rash and in another patient
due to grade 1 paresthesia; these decisions were made by the
treating physician and were not mandated by the study
protocol. No infectious complications were seen.
Treatment Outcome
Every patient successfully received the three planned
cycles of chemotherapy; however, in two cases, thalidomide
treatment was stopped because of toxicity. The total number
of cycles administered was 66 with an average dose intensity
of 96%. The dose of gemcitabine was reduced by one dose
level on 18 occasions and by two dose levels on two occa-
sions. Administration of gemcitabine was delayed twice by 1
week in cycle 2. Gemcitabine on day 8 was omitted twice,
both times in cycle 3. In one patient, the thalidomide dose
TABLE 1. Patient Characteristics, N  22
Median age (range) 53 (32–78)
Evaluated for toxicity 22 (100%)
Evaluated for responsea 20 (91%)
Sex
Female 12 (54.5%)
Male 10 (45.5%)
Histopathological type
Adenocarcinoma 13 (59.1%)
Squamous cell
carcinoma
6 (27.3%)
Adenosquamous type 2 (9.1%)
Other unspecified 1 (4.5%)
Disease stage
IIB 7 (31.81%)
IIIA 14 (63.64%)
IIIB 1 (4.54%)
Location of primary disease
Right upper lobe 12 (54.55%)
Right middle lobe 1 (4.55%)
Right lower lobe 3 (13.64%)
Left upper lobe 4 (18.18%)
Left lower lobe 3 (13.64%)
Performance status (Karnofsky score)
100% 15 (68%)
90% 6 (27%)
80% 1 (4%)
Smoking status
Smoking 18 (81%)
Nonsmoking 3 (14%)
Unknown 1 (4%)
a Two patients stopped thalidomide after day 1 of the first cycle due to toxicity.
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was reduced to 150 mg because of grade 2 somnolence and
later to 100 mg for grade 2 fatigue. Of 20 evaluable patients,
there were 14 confirmed PRs (70%). In total, four patients
(20%) had SD, and two patients (10%) had PD. Tumors were
resected in 14 patients (70%), which included 10 lobectomies
(45.5%), 1 bilobectomy (4.5%), and 3 pneumonectomies
(13.64%). Of the 14 patients who underwent surgery, 12 were
categorized as PR, one as SD, and one as PD. Five patients
who were not operated were treated with chemoradiotherapy
(22.72%). One patient (4.5%) had another chemotherapy
regimen and then surgery. The median duration of follow-up
was 23 months (range: 8–56 months). Eight patients (37%)
died of recurrent disease during follow-up. The TNM staging
of each patient along with response, tumor resection, and
recurrence is shown in Table 2. Overall survival was 3.6
years (95% CI: 1.938–). Disease-free survival was 1.75
years (95% CI: 1.117–2.954).
Serum Markers
The levels of serum markers before and after treat-
ment are summarized in Table 3. Only 12 patients were
available for measuring serum markers before and after
treatment. Five patients declined to participate in the
correlative study, and five declined to provide second
samples or withdrew from the study. We found no signif-
icant differences in the distribution of sex, TNM stage,
histology, response, or whether tumor was resected be-
tween those who participated in the biomarker substudy
and those who did not (Fisher’s exact test).
Table 4 shows the associations between serum markers
and disease-free survival as evaluated by univariate analysis.
An IL-8 level before treatment, greater than 10 pg/ml from
the mean baseline was associated with a 348% greater prob-
ability of recurrence (p  0.047). However, IL-8 increase of
at least 10 pg/ml after treatment corresponded to a 97%
reduction in the probability of recurrence (p  0.034). A
leptin level before treatment of 100 pg/ml higher than the
mean baseline corresponded to a 7% greater probability of
recurrence (p  0.034). A 100 pg/ml increase in the level of
angiopoietin after treatment when compared with before
corresponded to a 57% reduction in the probability of recur-
rence (p  0.052).
TABLE 2. TNM Stage and Treatment Outcome
TNM Response Resected Recurrence
T3N0M0 PR No Yes
T3N0M0 SD No Yes
T3N0M0 SD No No
T3N0M0 PR Yes Yes
T3N0M0 PR Yes No
T2N1M0 NA NA Yes
T3N1M0 PR Yes No
T1N2M0 PD No Yes
T1N2M0 PD Yes Yes
T1N2M0 PR Yes No
T1N2M0 PR Yes No
T1N2M0 SD Yes No
T1N2M0 NA NA NA
T2N2M0 PR No Yes
T2N2M0 PR Yes No
T2N2M0 PR Yes Yes
T2N2M0 PR Yes Yes
T2N2M0 PR Yes No
T3N2M0 PR Yes No
T3N2M0 PR Yes Yes
T3N2M0 PR Yes No
T3N3M0 SD No No
PR, partial response; SD, stable disease; PD, progressive disease; NA, no data
available.
TABLE 3. Before-and-After Changes in Serum Marker
N Mean (95% CI)
Overall 22
Past 1 d of first cycle 20
Angiopoietin 2 (pg/ml)
Before study 15 426.3 (252.4–600.3)
After study 13 373.5 (213.3–533.7)
Change 12 61.4 (179.1 to 56.3)
Follistatin (pg/ml)
Before study 15 399.8 (324.7–474.9)
After study 13 296.0 (238.7–353.3)
Change 12 104.9 (220.8–11.0)
HGF (pg/ml)
Before study 15 873.9 (737.0–1010.9)
After study 13 843.6 (666.6–1020.6)
Change 12 26.4 (295.3 to 242.5)
IL-8 (pg/ml)
Before study 15 19.5 (13.3–25.7)
After study 13 17.4 (12.7–2.21)
Change 12 2.2 (8.6 to 4.2)
G-CSF (pg/ml)
Before study 15 91.4 (65.9–11.7)
After study 13 65.6 (45.8–85.5)
Change 12 24.8 (57.1 to 7.5)
PDGF-BB (pg/ml)
Before study 15 1738.2 (1056.2–2420.2)
After study 13 1291.0 (785.0–1797.1)
Change 12 390.0 (1526.8 to 746.9)
VEGF (pg/ml)
Before study 15 66.0 (26.1–105.9)
After study 13 47.9 (30.9–64.9)
Change 12 25.6 (80.0 to 28.8)
Leptin (pg/ml)
Before study 15 2225.9 (1456.6–2995.2)
After study 13 2684.9 (1236.8–4132.9)
Change 12 20.7 (918.2 to 959.6)
PECAM 1 (pg/ml)
Before study 15 3473.2 (2833.8–4112.6)
After study 13 3473.2 (2772.1–4174.2)
Change 12 130.2 (1167.7 to 907.4)
HGF, hepatocyte growth factor; IL-8, interleukin-8; G-CSF, granulocyte colony-
stimulating factor; PDGF-BB, platelet-derived growth factor-; VEGF, vascular endo-
thelial growth factor; PECAM 1, platelet/endothelial cell adhesion molecule 1.
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Table 5 shows the associations between serum markers
and overall survival as evaluated by univariate analysis. A
leptin level before treatment of 100 pg/ml higher than the
mean baseline corresponded to a 15% greater probability of
death (p 0.029). A PECAM 1 level before treatment of 100
pg/ml higher than the mean baseline corresponded to a 6%
greater probability of death (p  0.08). A 100 pg/ml increase
in the PECAM 1 level after treatment when compared with
before corresponded to a 5% reduction in the probability of
death (p  0.055). A 100 pg/ml increase in angiopoietin after
treatment when compared with before corresponded to a 70%
reduction in the probability of death (p  0.09). A 100 pg/ml
increase in hepatocyte growth factor levels after treatment
when compared with before corresponded to a 33% reduction
in the probability of death (p  0.097). A 10 pg/ml increase
in IL-8 levels after treatment when compared with before
corresponded to a 51% reduction in the probability of death
(p  0.095). A 10 pg/ml increase in VEGF levels after
treatment when compared with before corresponded to a 29%
reduction in the probability of death (p  0.052).
DISCUSSION
One of the strategies for improving the activity of
chemotherapy is to combine it with antiangiogenic agents. In
TABLE 4. Univariate Analysis of Correlation Between Serum markers and Disease
Free Survival
N Deaths HR (95% CI) p
Overall 22
Past 1 d of first cycle 20
Angiopoietin 2 (pg/ml)
Before study 15 8 1.09 (0.73–1.63) Per 100 unit increase 0.664
After study 13 6 0.66 (0.35–1.24) 0.195
Change 12 6 0.43 (0.19–1.01) 0.052
Follistatin (pg/ml)
Before study 15 8 1.30 (0.74–2.29) Per 100 unit increase 0.364
After study 13 6 0.54 (0.19–1.52) 0.243
Change 12 6 0.81 (0.54–1.21) 0.302
HGF (pg/ml)
Before study 15 8 1.30 (0.89–1.89) Per 100 unit increase 0.175
After study 13 6 0.85 (0.63–1.15) 0.305
Change 12 6 0.810 (0.63–1.04) 0.100
IL-8 (pg/ml)
Before study 15 8 3.48 (1.01–11.91) Per 10 unit increase 0.047
After study 13 6 0.46 (0.11–1.91) 0.286
Change 12 6 0.03 (0.001–0.77) 0.034
GCSF (pg/ml)
Before study 15 8 1.07 (0.94–1.23) Per 10 unit increase 0.304
After study 13 6 0.91 (0.68–1.22) 0.539
Change 12 6 0.95 (0.84–1.08) 0.422
PDGF BB (pg/ml)
Before study 15 8 1.01 (0.94–1.09) Per 100 unit increase 0.746
After study 13 6 0.90 (0.78–1.02) 0.101
Change 12 6 0.97 (0.93–1.02) 0.249
VEGF (pg/ml)
Before study 15 8 1.04 (0.91–1.18) Per 10 unit increase 0.602
After study 13 6 0.78 (0.53–1.15) 0.204
Change 12 6 0.96 (0.86–1.08) 0.509
Leptin (pg/ml)
Before study 15 8 1.07 (1.01–1.15) Per 100 unit increase 0.034
After study 13 6 1.02 (0.98–1.06) 0.335
Change 12 6 1.01 (0.95–1.08) 0.725
PECAM 1 (pg/ml)
Before study 15 8 1.03 (0.97–1.09) Per 100 unit increase 0.410
After study 13 6 0.95 (0.85–1.06) 0.389
Change 12 6 0.98 (0.94–1.02) 0.300
HR, hazard ratio; CI, confidence interval; HGF, hepatocyte growth factor; IL-8, interleukin-8; G-CSF, granulocyte
colony-stimulating factor; PDGF-BB, platelet-derived growth factor-; VEGF, vascular endothelial growth factor; PECAM
1, platelet/endothelial cell adhesion molecule 1.
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advanced NSCLC, adding bevacizumab to a chemotherapy
regimen has been shown to improve progression-free survival
in two trials; however, improvements in overall survival were
only seen in one of these trials.15,16 In locally advanced
NSCLC, overall survival can be improved by downstaging of
disease to make a tumor operable. In our trial, we selected
thalidomide as an antiangiogenic agent for treating patients
with locally advanced, inoperable NSCLC. In one of the first
classic trials of neoadjuvant therapy, 60% of patients with
stage IIIA NSCLC achieved a clinical response after receiv-
ing chemotherapy consisting of mitomycin, ifosfamide, and
cisplatin, and 76% of them had resectable tumor.7 In another
trial, 35% of patients with resectable stage IIIA NSCLC had
a “major clinical response” after three cycles of chemother-
apy consisting of cyclophosphamide, cisplatin, and etopo-
side.8 In a study reported by Elias et al.,17 a 65% response rate
(6% CR) was seen in patients with stage IIIA NSCLC treated
neoadjuvantly with cisplatin, 5-fluorouracil, and leucovorin.
Thoracotomy was performed in 82% of patients with a 75%
rate of complete resection. In a phase II trial for patients with
stage IB to IIIA NSCLC treated with three different chemo-
therapy schedules, including cisplatin and gemcitabine, a
clinical response was seen in 77% of all patients and 67%
with N2 disease, resulting in 73% of all participants going on
TABLE 5. Univariate Analysis of Correlation Between Serum Markers and Overall
Survival
N Deaths HR (95% CI) p
Overall 22
Past 1 d of first cycle 20
Angiopoietin 2 (pg/ml)
Before study 15 5 1.39 (0.59–3.24) Per 100 unit increase 0.451
After study 13 4 0.63 (0.28–1.41) 0.259
Change 12 4 0.30 (0.07–1.21) 0.090
Follistatin (pg/ml)
Before study 15 5 1.75 (0.82–3.72) Per 100 unit increase 0.147
After study 13 4 0.47 (0.13–1.73) 0.255
Change 12 4 0.65 (0.39–1.10) 0.107
HGF (pg/ml)
Before study 15 5 1.41 (0.84–2.38) Per 100 unit increase 0.197
After study 13 4 0.80 (0.55–1.18) 0.259
Change 12 4 0.67 (0.42–1.07) 0.097
IL-8 (pg/ml)
Before study 15 5 1.36 (0.66–2.79) Per 10 unit increase 0.405
After study 13 4 0.37 (0.07–1.90) 0.231
Change 12 4 0.49 (0.21–1.13) 0.095
G-CSF (pg/ml)
Before study 15 5 1.09 (0.92–1.28) Per 10 unit increase 0.342
After study 13 4 0.91 (0.66–1.26) 0.572
Change 12 4 0.93 (0.80–1.08) 0.337
PDGF-BB (pg/ml)
Before study 15 5 1.04 (0.95–1.14) Per 100 unit increase 0.407
After study 13 4 0.93 (0.80–1.08) 0.362
Change 12 4 0.96 (0.89–1.03) 0.201
VEGF (pg/ml)
Before study 15 5 1.28 (0.91–1.81) Per 10 unit increase 0.162
After study 13 4 0.73 (0.44–1.23) 0.242
Change 12 4 0.71 (0.51–1.00) 0.052
Leptin (pg/ml)
Before study 15 5 1.15 (1.03–1.30) Per 100 unit increase 0.017
After study 13 4 1.06 (0.98–1.16) 0.152
Change 12 4 1.00 (0.91–1.10) 0.979
PECAM 1 (pg/ml)
Before study 15 5 1.06 (0.99–1.14) Per 100 unit increase 0.080
After study 13 4 0.92 (0.80–1.05) 0.199
Change 12 4 0.95 (0.90–1.00) 0.055
HR, hazard ratio; CI, confidence interval; HGF, hepatocyte growth factor; IL-8, interleukin-8; G-CSF, granulocyte
colony-stimulating factor; PDGF-BB, platelet-derived growth factor-; VEGF, vascular endothelial growth factor; PECAM
1, platelet/endothelial cell adhesion molecule 1.
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to surgery.18 Neoadjuvant carboplatin (AUC 5 on day 1) in
combination with gemcitabine (1250 mg/m2 on days 1 and 8)
was tested in 37 patients with stage III disease, resulting in an
overall response rate of 51%. Neither CR nor PD was seen in
this study.19 In 40 patients with stage I/II NSCLC, carboplatin
(AUC  5.5 on day1) and gemcitabine (1000 mg/m2 on days
1 and 8) induced PR in 20% of patients, and CR in no
patients.20 In our study, 90% of patients achieved a clinical
response (PR: 70%, SD: 20%), with 70% of all patients being
referred to surgery after neoadjuvant therapy. It is notable
that before enrollment in our study every subject was deemed
inoperable by a surgeon.
Because of the small sample of patients and noncompara-
tive nature of our study, none of the levels or changes in serum
proteins analyzed herein can be proposed as biomarkers of
treatment response. However, our preliminary results are en-
couraging and warrant further evaluation. The observed serum
markers changes and their associations with recurrence and
survival may not be the result of a direct effect of thalidomide
and chemotherapy combination, but rather an indirect measure
of antitumor activity in which increased cytokines levels after
treatment reflect a rebound in production of these proteins by
stressed tumor cells. Recent studies have shown that thalidomide
decreased VEGF levels in an experimental model21 and in
humans with multiple myeloma.22,23 This is consistent with our
findings of a reduced level of serum VEGF after treatment.
However, we were unable to confirm the report of a correlation
between higher baseline VEGF levels and improved progression
free survival.23 Although there is no published study describing
the effect of thalidomide on IL-8 levels in patients with cancer,
thalidomide has been shown to decrease IL-8 levels in other
diseases,24–26 which is consistent with our observation. How-
ever, in our patients, an increase in IL-8 levels after treatment
was associated with a significant decrease in risk of disease
recurrence.
Taking into consideration that the disease of every
participant in our study was initially evaluated as unresect-
able, we conclude that the combination of gemcitabine, car-
boplatin, and thalidomide has activity in locally advanced
NSCLC and can be recommended for further investigation.
However, the contribution of thalidomide to the efficacy of
this regimen remains uncertain.
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